MERCK
20.12.2021 14:02:06 CET | Business Wire | Press release
Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.
“Cladribine has a unique mechanism of action which is relevant in antibody-mediated disease such as NMOSD and gMG. In exploratory studies, cladribine demonstrated promising results in these diseases. These data have prompted us to initiate further development with cladribine in gMG and NMOSD to potentially bring a new therapeutic option to patients and expand our portfolio in this area,” said Danny Bar-Zohar, MD, Head of Global Development for the biopharma business of Merck.
Cladribine is a well characterized molecule that has been extensively studied across MS and oncologic disorders and has shown promising results in exploratory studies in gMG and NMOSD. Merck plans to leverage its existing capabilities to further develop an oral cladribine product tailored specifically for these indications. The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.
Generalized myasthenia gravis is a disease in which patients experience weakness in ocular, limb, and respiratory muscles and that has a significant impact on Quality of Life. It is estimated that 700,000 people around the world are living with gMG. NMOSD, also known as Devic´s disease, is an autoimmune disease, often misdiagnosed as MS due to similar symptoms. NMOSD is estimated to impact 200,000 people around the world.
About Chord Therapeutics
Chord Therapeutics is a Swiss-based clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. Chord is advancing its lead drug candidate, CRD1 (cladribine), for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and generalized myasthenia gravis (gMG). Chord Therapeutics was founded in 2014 and launched in October 2020 with Series A funding by its sole investor, Omega Funds, a leading international venture capital firm focused on delivering impactful medicines to patients.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Consumer Trends 2027: Trust, Transparency and Control Take Centre Stage4.11.2026 06:01:00 CET | Press release
Consumers are no longer placing full trust in brands, technology or the future itself. As uncertainty becomes a permanent feature of daily life, greater value is being placed on reliability, transparency and immediate proof of value. Euromonitor International's Top Global Consumer Trends 2027 report finds consumers seeking greater control as uncertainty reshapes consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103010032/en/ Euromonitor's Top global consumer trends 2027 Drawing on insights from Passport, Euromonitor International's AI-powered market intelligence platform, the report finds consumers looking for balance and control in a world they no longer expect to be certain. Across markets, consumers are placing greater value on reliability, transparency, community and immediate, tangible benefits. “Consumers are no longer simply buying products or services; they're looking for confidence," said Ali Ang
H2SITE Selected for EU Innovation Fund Support to Advance Industrial-Scale Ammonia Cracking in Rotterdam4.11.2026 06:00:00 CET | Press release
The proposed Rotterdam facility would advance the industrial deployment of H2SITE’s hydrogen technology, with a planned production capacity of 20 tons of hydrogen per day. H2SITE has been selected for support from the European Union’s Innovation Fund for the development of an industrial-scale ammonia cracking project in Rotterdam, subject to the formalisation of the grant agreement. The selection marks an important milestone in the company’s work to scale its technology and support the decarbonisation of hard-to-abate industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103379287/en/ Aerial view of the Botlek in Rotterdam. Photo: T.W. van Urk / Shutterstock The project aims to recover and purify hydrogen from imported ammonia close to industrial consumption centres, advancing the industrial deployment of H2SITE’s technology. H2SITE is working closely with industrial stakeholders in Rotterdam to define the project’s
The Estée Lauder Companies Announces Fiscal 2030 Ambition at Its Capital Markets Experience: China Ecosystem Immersion Event4.11.2026 06:00:00 CET | Press release
Sustainable Mid-Single-Digit Organic Net Sales Growth through Fiscal 2030 Adjusted Operating Margin of 16.5%-18.5% in Fiscal 2030Double-Digit Adjusted EPS Growth through Fiscal 2030 The Estée Lauder Companies Inc. (NYSE: EL) today announced its fiscal 2030 ambition at its Capital Markets Experience: China Ecosystem Immersion event in Shanghai, China. Stéphane de La Faverie, President and Chief Executive Officer, and Akhil Shrivastava, Executive Vice President and Chief Financial Officer, outlined the Company’s targets, including its plans to build on the progress of its Beauty Reimagined strategic vision and the execution of its One ELC operating model to deliver sustainable growth while continuing to drive stronger operating leverage and expanded profitability. “We are now entering a new chapter, moving beyond restoring growth to accelerating sustainable, profitable growth and creating long-term value. Our fiscal 2027 outlook reflects this momentum, with accelerating organic sales gro
FPT, Airbus’ Skywise, and Vietnam Airlines Partner to Advance AI-Powered Airline Operations4.11.2026 05:21:00 CET | Press release
FPT, Vietnam Airlines and Skywise, Airbus' digital services company, have signed a Memorandum of Understanding (MoU) to explore the development of AI-powered services. By combining Vietnam Airlines’ operational expertise and data, insights from the Skywise platform, and FPT’s capabilities in aviation technology, systems integration and AI engineering, the collaboration will identify practical AI use cases that could enhance performance, strengthen resilience and support better-informed decision-making. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103646801/en/ The MOU was announced at the Vietnam Aerospace Forum (VAF) in Hanoi on 4 November 2026. The programme will initially focus on fleet reliability, technical operations and disruption management. By combining Skywise’s insights with maintenance planning, parts readiness and flight schedules, the parties will explore AI applications to improve aircraft availability an
IFF Reports Third Quarter 2026 Results3.11.2026 22:30:00 CET | Press release
Delivered Strong Sales, Profit and Cash Flow Performance in Third Quarter 2026Raising Low-End of Full Year 2026 Financial Guidance RangesRecently Completed $500M Share Repurchase AuthorizationFood Ingredients Divestiture Progressing Well and On Track to Close by End of Second Quarter 2027 IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2026. Results are presented on a continuing operations basis, excluding the Food Ingredients business and other minor perimeter adjustments (the “Food Ingredients disposal group”), and the Soy Crush, Concentrates, and Lecithin businesses (the “SCL disposal group”). The Food Ingredients disposal group and the SCL disposal group are reported as discontinued operations. Management Commentary “IFF delivered a solid third quarter, with improved sales and profitability across all divisions,” said Erik Fyrwald, CEO of IFF. “Taste and Scent delivered strong top- and bottom-line results, and Health & Biosciences improved modes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom